Exobiosphere joins EYnovation™ to accelerate Space-based Biotech

Exobiosphere has been selected to take part in the EYnovation™ program, an initiative by Ernst & Young (EY) designed to support high-potential startups and scaleups through strategic business advisory, access to an extensive network, and tailored growth acceleration services. This partnership marks another key milestone in the company’s mission to redefine drug discovery through space-based biotechnology.

Specializing in high-throughput drug screening in microgravity, Exobiosphere leverages the unique properties of space to enhance disease modeling, improve drug efficacy, and accelerate pharmaceutical R&D. Through EYnovation™, the company will receive direct support from EY’s industry experts to refine business strategies, strengthen operational efficiency, and expand its global impact in the biotech and pharmaceutical sectors.

“Exobiosphere is developing a niche market that will scale dramatically over the coming years. Partnering with one of the best global firms will support this growth and strengthen commercial strategy,” said Kyle Acierno, CEO of Exobiosphere.

The EYnovation™ program has a strong track record of empowering startups to achieve international success. Through its exclusive partnership with the Startup World Cup, EYnovation™ has enabled Luxembourg-based startups to compete on a global stage, gaining industry recognition and attracting key investors.

“At EY, we are committed to supporting breakthrough innovation, and Exobiosphere is a perfect example of a company pushing the boundaries of what’s possible. We are proud to support their growth and help accelerate the future of biotech in space,” said Frédéric Munch, EY Luxembourg.

With biotech and space innovation converging, this collaboration comes at a critical time, offering new opportunities to develop next-generation therapeutics. As Exobiosphere continues to expand, the EYnovation™ program will provide essential tools to optimize its commercial strategy, attract key partners, and bring space-enabled drug discovery to more pharmaceutical players worldwide.